[FLT3-ITD Mutation in Newly Diagnosed Patients with Acute Promyelocytic Leukemia]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1615-1621. doi: 10.7534/j.issn.1009-2137.2016.06.001.
[Article in Chinese]

Abstract

Objective: To evaluate the influence of FLT3-ITD mutation on long term survival of newly diagnosed patients with acute promyelocytic leukemia (APL).

Methods: Long term survival of 170 newly diagnosed APL patients was retrospective analyzed. Mutation rate of FLT3-ITD was assayed, and its influence on disease-free survival(DFS) or overall survival (OS) was analyzed.

Results: The mutation rate of FLT3-ITD in newly diagnosed patients with APL was 14.1%. WBC count at diagnosis was higer in FLT3-ITD positive group than that in negative group, and the mutation rate of FLT3-ITD was highest in high risk group. Induction death rate in FLT3-ITD positive and negative group were 12.5% and 2.9%, respectively (P=0.031). Complete remission(CR) rate in 2 groups were 83.3% and 97.1%(P=0.004). The 5-year OS rates in 2 groups were 87.5±6.8% and 90.6±2.6% (P=0.740). The 5-year DFS in 2 groups were 82.8±9.1% and 83.6±3.4%(P=0.928).

Conclusion: FLT3-ITD mutation is related with high peripheral white blood cell count in APL, the APL with FLT3-ITD mutation has higher induction death rate and lower CR rate than those in that without FLT3-ITD mutation, but FLT3-ITD mutation did not affect on long term DFS and OS.

MeSH terms

  • Disease-Free Survival
  • Humans
  • Leukemia, Myeloid, Acute
  • Leukemia, Promyelocytic, Acute*
  • Leukocyte Count
  • Mutation
  • Prognosis
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • fms-Like Tyrosine Kinase 3

Substances

  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3